These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 19375807)

  • 1. Ligand binding and micro-switches in 7TM receptor structures.
    Nygaard R; Frimurer TM; Holst B; Rosenkilde MM; Schwartz TW
    Trends Pharmacol Sci; 2009 May; 30(5):249-59. PubMed ID: 19375807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ghrelin receptor inverse agonists: identification of an active peptide core and its interaction epitopes on the receptor.
    Holst B; Lang M; Brandt E; Bach A; Howard A; Frimurer TM; Beck-Sickinger A; Schwartz TW
    Mol Pharmacol; 2006 Sep; 70(3):936-46. PubMed ID: 16798937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The minor binding pocket: a major player in 7TM receptor activation.
    Rosenkilde MM; Benned-Jensen T; Frimurer TM; Schwartz TW
    Trends Pharmacol Sci; 2010 Dec; 31(12):567-74. PubMed ID: 20870300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agonist-induced conformational changes in bovine rhodopsin: insight into activation of G-protein-coupled receptors.
    Bhattacharya S; Hall SE; Vaidehi N
    J Mol Biol; 2008 Oct; 382(2):539-55. PubMed ID: 18638482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for ligand binding and specificity in adrenergic receptors: implications for GPCR-targeted drug discovery.
    Huber T; Menon S; Sakmar TP
    Biochemistry; 2008 Oct; 47(42):11013-23. PubMed ID: 18821775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conserved water-mediated hydrogen bond network between TM-I, -II, -VI, and -VII in 7TM receptor activation.
    Nygaard R; Valentin-Hansen L; Mokrosinski J; Frimurer TM; Schwartz TW
    J Biol Chem; 2010 Jun; 285(25):19625-36. PubMed ID: 20395291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chapter 8. Activation mechanisms of chemokine receptors.
    Jensen PC; Rosenkilde MM
    Methods Enzymol; 2009; 461():171-90. PubMed ID: 19480919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox.
    Langmead CJ; Christopoulos A
    Trends Pharmacol Sci; 2006 Sep; 27(9):475-81. PubMed ID: 16889837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the CXCR3 chemokine receptor through anchoring of a small molecule chelator ligand between TM-III, -IV, and -VI.
    Rosenkilde MM; Andersen MB; Nygaard R; Frimurer TM; Schwartz TW
    Mol Pharmacol; 2007 Mar; 71(3):930-41. PubMed ID: 17170198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors.
    Hoare SR
    Drug Discov Today; 2005 Mar; 10(6):417-27. PubMed ID: 15808821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular basis of inverse agonism in a G protein-coupled receptor.
    Vilardaga JP; Steinmeyer R; Harms GS; Lohse MJ
    Nat Chem Biol; 2005 Jun; 1(1):25-8. PubMed ID: 16407989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A second disulfide bridge from the N-terminal domain to extracellular loop 2 dampens receptor activity in GPR39.
    Storjohann L; Holst B; Schwartz TW
    Biochemistry; 2008 Sep; 47(35):9198-207. PubMed ID: 18693759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis for agonism in the BB3 receptor: an epitope located on the interface of transmembrane-III, -VI, and -VII.
    Gbahou F; Holst B; Schwartz TW
    J Pharmacol Exp Ther; 2010 Apr; 333(1):51-9. PubMed ID: 20065020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequence-derived three-dimensional pharmacophore models for G-protein-coupled receptors and their application in virtual screening.
    Klabunde T; Giegerich C; Evers A
    J Med Chem; 2009 May; 52(9):2923-32. PubMed ID: 19374402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms.
    Bridges TM; Lindsley CW
    ACS Chem Biol; 2008 Sep; 3(9):530-41. PubMed ID: 18652471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanism of 7TM receptor activation--a global toggle switch model.
    Schwartz TW; Frimurer TM; Holst B; Rosenkilde MM; Elling CE
    Annu Rev Pharmacol Toxicol; 2006; 46():481-519. PubMed ID: 16402913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors.
    Kenakin T
    Trends Pharmacol Sci; 2007 Aug; 28(8):407-15. PubMed ID: 17629960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5.
    Andrews G; Jones C; Wreggett KA
    Mol Pharmacol; 2008 Mar; 73(3):855-67. PubMed ID: 18042736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. '7TM receptor allostery: putting numbers to shapeshifting proteins.
    Kenakin TP
    Trends Pharmacol Sci; 2009 Sep; 30(9):460-9. PubMed ID: 19729207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism.
    Holst B; Mokrosinski J; Lang M; Brandt E; Nygaard R; Frimurer TM; Beck-Sickinger AG; Schwartz TW
    J Biol Chem; 2007 May; 282(21):15799-811. PubMed ID: 17371869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.